Schroecksnadel and collaborators seem a bit skeptical about our recent publication on ␤2 microglobulin (␤2M) 1 and about the laudatory editorial 2 that accompanied it. Our article described the discovery that blood levels of ␤2M correlate with the severity of peripheral arterial disease (PAD) as assessed by the ankle-brachial index or treadmill testing. This novel finding arose from an agnostic high-throughput proteomic profiling effort using surface-enhanced laser desorption and ionization time-of-flight mass spectroscopy. This is a candidate-generating approach, in contrast to the more common candidate-based approach to proteomic profiling. The major advantage of the candidate-generating approach is that it provides for the discovery of new biomarkers for disease and potentially new insights into pathobiology. We hypothesized that repeated bouts of ischemia-reperfusion in the lower extremities could cause the expression and release of proteins that would be characteristic of the ischemic musculoskeletal circulation and that these could be detected in the systemic circulation. This agnostic approach led to an unexpected finding, the correlation of ␤2M with the severity of PAD. Notwithstanding the unreferenced comment of Schroeksnadel and colleagues, there are no previous reports suggesting ␤2M as a biomarker for PAD.
On the other hand, we recognize that ␤2M has been used previously as a biomarker of renal insufficiency, a point raised by our Austrian colleagues. Accordingly, we performed a multivariate analysis that included the estimated glomerular filtration rate as a covariable. Even after consideration of renal function, ␤2M remained a predictor for the ankle-brachial index. The Innsbruck group reminds us that ␤2M is elevated in inflammatory states, an association that is familiar to us. Inflammation is an integral component of the pathobiology of PAD, and the level of C-reactive protein (an accepted biomarker of inflammation) has been correlated with severity of PAD. 3 In our study, the odds ratio for the diagnosis of PAD for an elevated C-reactive protein level was 1.3, as opposed to an odds ratio of 7.2 for an elevated ␤2M.
Our findings are now supported by an elegant study from Shinkai and coworkers. 4 In their prospective longitudinal study of elderly Japanese subjects, ␤2M was an independent predictor of death after consideration of renal insufficiency and inflammation. Indeed, ␤2M seems to be a better prognosticator than cystatin C (thought to be a superior marker for renal dysfunction) 5 or C-reactive protein. Shinkai and colleagues 4 did not measure the ankle-brachial index; however, they made the intriguing observation that ␤2M was negatively associated with usual walking speed. It is well known that patients with PAD have reduced walking speeds. 6 This casual observation of Shinkai and coworkers 4 may have reflected the prevalence of PAD among their subjects with elevated ␤2M levels.
We do not disagree with our Austrian colleagues that ␤2M levels will be elevated by renal insufficiency and inflammation. The elevation of ␤2M levels in our patients with PAD is likely multifactorial, reflecting these and other adverse influences on the vessel wall. Taken together with the study of Shinkai and coworkers, 4 however, our study suggests that ␤2M provides independent predictive value for the diagnosis of PAD. Interesting areas for future investigation include elucidation of the mechanisms that increase ␤2M in vascular disease; determination of its role in vascular pathogenesis; characterization of the effect of medical therapy on ␤2M levels; and assessment of therapeutic interventions targeting ␤2M so as to reduce the morbidity and mortality rates associated with PAD.
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